Opsis Therapeutics, LLC
Industry
- Pharmaceuticals
See more in Biomedtracker
Latest on Opsis Therapeutics, LLC
Scrip
• By Kevin Grogan
The excitement surrounding positive data from a small early-stage study evaluating Bayer AG subsidary BlueRock Therapeutics LP 's bemdaneprocel for Parkinson's disease is merited, according to the
Scrip
• By Joseph Haas and John Davis
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genentech/Pieris Pact Follows Abandoned